-+ 0.00%
-+ 0.00%
-+ 0.00%

We Ran A Stock Scan For Earnings Growth And DongKook Pharmaceutical (KOSDAQ:086450) Passed With Ease

Simply Wall St·11/19/2026 23:13:44
Listen to the news

Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks' without any revenue, let alone profit. Unfortunately, these high risk investments often have little probability of ever paying off, and many investors pay a price to learn their lesson. While a well funded company may sustain losses for years, it will need to generate a profit eventually, or else investors will move on and the company will wither away.

So if this idea of high risk and high reward doesn't suit, you might be more interested in profitable, growing companies, like DongKook Pharmaceutical (KOSDAQ:086450). While profit isn't the sole metric that should be considered when investing, it's worth recognising businesses that can consistently produce it.

DongKook Pharmaceutical's Earnings Per Share Are Growing

The market is a voting machine in the short term, but a weighing machine in the long term, so you'd expect share price to follow earnings per share (EPS) outcomes eventually. That makes EPS growth an attractive quality for any company. DongKook Pharmaceutical managed to grow EPS by 17% per year, over three years. That's a good rate of growth, if it can be sustained.

One way to double-check a company's growth is to look at how its revenue, and earnings before interest and tax (EBIT) margins are changing. DongKook Pharmaceutical maintained stable EBIT margins over the last year, all while growing revenue 13% to ₩980b. That's progress.

The chart below shows how the company's bottom and top lines have progressed over time. Click on the chart to see the exact numbers.

earnings-and-revenue-history
KOSDAQ:A086450 Earnings and Revenue History November 19th 2026

See our latest analysis for DongKook Pharmaceutical

The trick, as an investor, is to find companies that are going to perform well in the future, not just in the past. While crystal balls don't exist, you can check our visualization of consensus analyst forecasts for DongKook Pharmaceutical's future EPS 100% free.

Are DongKook Pharmaceutical Insiders Aligned With All Shareholders?

It should give investors a sense of security owning shares in a company if insiders also own shares, creating a close alignment their interests. DongKook Pharmaceutical followers will find comfort in knowing that insiders have a significant amount of capital that aligns their best interests with the wider shareholder group. Notably, they have an enviable stake in the company, worth ₩283b. That equates to 24% of the company, making insiders powerful and aligned with other shareholders. Looking very optimistic for investors.

Should You Add DongKook Pharmaceutical To Your Watchlist?

One important encouraging feature of DongKook Pharmaceutical is that it is growing profits. For those who are looking for a little more than this, the high level of insider ownership enhances our enthusiasm for this growth. The combination definitely favoured by investors so consider keeping the company on a watchlist. Now, you could try to make up your mind on DongKook Pharmaceutical by focusing on just these factors, or you could also consider how its price-to-earnings ratio compares to other companies in its industry.

While opting for stocks without growing earnings and absent insider buying can yield results, for investors valuing these key metrics, here is a carefully selected list of companies in KR with promising growth potential and insider confidence.

Please note the insider transactions discussed in this article refer to reportable transactions in the relevant jurisdiction.